Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia

被引:69
作者
Fournier, S
Pavageau, W
Feuillhade, M
Deplus, S
Zagdanski, AM
Verola, O
Dombret, H
Molina, JM
机构
[1] St Louis Hosp, Dept Infect Dis, F-75010 Paris, France
[2] St Louis Hosp, Parasitol Lab, F-75010 Paris, France
[3] St Louis Hosp, Div Ophthalmol, F-75010 Paris, France
[4] St Louis Hosp, Div Radiol, F-75010 Paris, France
[5] St Louis Hosp, Div Anatomopathol, F-75010 Paris, France
[6] St Louis Hosp, Div Hematol, F-75010 Paris, France
关键词
D O I
10.1007/s10096-002-0841-y
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Trichosporon spp. is an emerging fungal pathogen in immunocompromised hosts, and disseminated infection is often fatal in neutropenic patients. Reported here is a case of disseminated infection in a neutropenic patient with acute leukaemia. After failure of amphotericin B and fluconazole therapy, the course of infection dramatically improved with voriconazole treatment. A literature search revealed 69 additional cases of disseminated Trichosporon spp. infections in neutropenic patients, and these are also reviewed. Clinical symptoms that suggest infection include fever, disseminated papulopustular cutaneous lesions and pulmonary involvement. Despite treatment with antifungal agents (amphotericin B, fluconazole), 78% of patients died. Voriconazole may represent a promising therapy for this life-threatening infection.
引用
收藏
页码:892 / 896
页数:5
相关论文
共 70 条
  • [1] ALBALLAA S, 1991, MYCOSES, V34, P317, DOI 10.1111/j.1439-0507.1991.tb00667.x
  • [2] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
    Ally, R
    Schürmann, D
    Kreisel, W
    Carosi, G
    Aguirrebengoa, K
    Dupont, B
    Hodges, M
    Troke, P
    Romero, AJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) : 1447 - 1454
  • [3] AZOLE THERAPY FOR TRICHOSPORONOSIS - CLINICAL-EVALUATION OF 8 PATIENTS, EXPERIMENTAL-THERAPY FOR MURINE INFECTION, AND REVIEW
    ANAISSIE, E
    GOKASLAN, A
    HACHEM, R
    RUBIN, R
    GRIFFIN, G
    ROBINSON, R
    SOBEL, J
    BODEY, G
    [J]. CLINICAL INFECTIOUS DISEASES, 1992, 15 (05) : 781 - 787
  • [4] COMPARATIVE EFFICACIES OF AMPHOTERICIN-B, TRIAZOLES, AND COMBINATION OF BOTH AS EXPERIMENTAL-THERAPY FOR MURINE TRICHOSPORONOSIS
    ANAISSIE, EJ
    HACHEM, R
    KARYOTAKIS, NC
    GOKASLAN, A
    DIGNANI, MC
    STEPHENS, LC
    TINU, CK
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (11) : 2541 - 2544
  • [5] BHANSALI S, 1986, CANCER, V58, P1630, DOI 10.1002/1097-0142(19861015)58:8<1630::AID-CNCR2820580808>3.0.CO
  • [6] 2-M
  • [7] Trichosporon beigelii:: a life-threatening pathogen in immunocompromised hosts
    Erer, B
    Galimberti, M
    Lucarelli, G
    Giardini, C
    Polchi, P
    Baronciani, D
    Gaziev, D
    Angelucci, E
    Izzi, G
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (07) : 745 - 749
  • [8] In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) : 198 - 202
  • [9] EVANS HL, 1980, CANCER, V45, P367, DOI 10.1002/1097-0142(19800115)45:2&lt
  • [10] 367::AID-CNCR2820450229&gt